spacer
home > ebr > summer 2017 > dissecting structures
PUBLICATIONS
European Biopharmaceutical Review

Dissecting Structures

The biosimilars market is yet to fully come to fruition, and the race is still on to obtain approval for a number of products within the European market. The EMA guidelines recommend the application of state-of-the-art characterisation studies to demonstrate that the structural and physico-chemical attributes of a biosimilar are comparable to the reference medicinal product (RMP). The higher order structure (HOS) aspects of the EMA biosimilar guidelines and the ICH Q6B guidelines are discussed below, including examples of the required analyses, detail regarding which analyses should be performed when and also how the data can assist in defining biosimilarity.Questions often arise as to which analytics should be performed within a biophysical characterisation study, when these tests should be performed and what the results will tell you about your product.

Thought Processes

Characterisation of a biopharmaceutical comprises a broader set of assessments when compared to release tests. In early development stages, all possible investigations are used to provide data that will allow an initial understanding of both the RMP and biosimilar. The information gained from these fundamental tests determines the analyses that will provide useful information as development proceeds. The tests for product release are a subset of these characterisation assays, chosen based on the data, critical quality attributes (CQAs) for the product, and any issues observed during product development such as propensity to unfold would require a secondary or tertiary structure-based release test.

Data from biological assays should be used in conjunction with analytical data to determine the product CQAs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Mark I Millichip is the Technical Director of Physico-Chemical Analysis at BioPharmaSpec and is responsible for managing all aspects of secondary and tertiary structural protein characterisation and aggregation profiles, as well as protein purification. He has worked in the field of biochemistry for 25 years in both academia and industry.

Dr Andrew J Reason is the founder, Chief Executive Officer and Managing Director of BioPharmaSpec. He has 25 years of experience in analysis of novel and biosimilar biopharmaceuticals and has been involved in the commercialisation of a number of analytical methods for characterising proteins. In addition to his scientific and managerial duties, Andrew is also a visiting professor at the University of Warwick, UK, and has contributed to many industry publications and is a regular presenter at conferences.

spacer
Dr Mark I Millichip
spacer
spacer
spacer
Dr Andrew J Reason
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics announces a research collaboration with GE Healthcare to extend the toolbox for production of biologics

Edinburgh, UK, 4th January 2017 – Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

9th Global Drug Delivery & Formulation Summit

12-14 March 2018, Maritim proArte Hotel Berlin

The DDF Summit brings the most interesting studies and exciting technologies to you. This year there will be 4 dedicated streams focusing on Small Molecules, Biologics, Technology & Innovation and for the first-time Device Development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement